Onco-hematology
The 5th edition of the WHO classification of hematolymphoid tumors: myeloid and histiocytic/dendritic neoplasms.
27 Jun, 2022 | 11:40h | UTCEditorial: The WHO Classification of Haematolymphoid Tumours – Leukemia
The 5th edition of the WHO classification of hematolymphoid tumors: lymphoid neoplasms.
27 Jun, 2022 | 11:38h | UTCEditorial: The WHO Classification of Haematolymphoid Tumours – Leukemia
M-A: Intravenous iron vs. oral iron vs. no iron with or without erythropoiesis‐ stimulating agents for cancer patients with anemia.
23 Jun, 2022 | 10:10h | UTC
5-year follow up of a RCT: Ruxolitinib versus best available therapy in inadequately controlled polycythemia vera without splenomegaly.
23 Jun, 2022 | 09:55h | UTCRuxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study – The Lancet Haematology (link to abstract – $ for full-text)
Original Study: Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
NEW online—5-year follow up of RESPONSE-2, a randomised, phase 3b study, supports the use of ruxolitinib as a second-line therapy of choice for patients with inadequately controlled polycythaemia vera without splenomegaly #mpnsm https://t.co/yuENmcJv0P pic.twitter.com/aogZJ6gonW
— The Lancet Haematology (@TheLancetHaem) May 19, 2022
RCT: Lisocabtagene maraleucel vs. standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma.
21 Jun, 2022 | 10:48h | UTCLisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Single-arm Phase II trial: Direct-acting antivirals as primary treatment for hepatitis C virus–associated indolent Non-Hodgkin Lymphomas.
20 Jun, 2022 | 00:51h | UTC
10-year outcomes of a RCT: Time to cure for childhood and young adult Acute Lymphoblastic Leukemia is independent of early risk factors.
20 Jun, 2022 | 00:49h | UTCTime to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Recommendations Statement: Diagnosis and treatment of systemic mastocytosis.
14 Jun, 2022 | 11:03h | UTC
Molecular international prognostic scoring system for myelodysplastic syndromes.
14 Jun, 2022 | 10:38h | UTCMolecular International Prognostic Scoring System for Myelodysplastic Syndromes – NEJM Evidence
2-year follow-up of a single-arm study: Ciltacabtagene Autoleucel, an Anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma.
13 Jun, 2022 | 07:34h | UTCOriginal Study: Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
In follow-up from CARTITUDE-1 trial of ciltacabtagene autoleucel in R/R MM, ORR was 97.9% and 82.5% had a stringent CR. 27-mo PFS was 54% and OS was 70.4% https://t.co/cnpzkg5yKM
— NatureRevClinOncol (@NatRevClinOncol) June 9, 2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
9 Jun, 2022 | 10:17h | UTC
International consensus classification of mature lymphoid neoplasms.
9 Jun, 2022 | 10:15h | UTC
Cardiac Magnetic Resonance Imaging–based screening for cardiac sarcoidosis in patients with atrioventricular block requiring temporary pacing.
8 Jun, 2022 | 10:41h | UTC
ESTRO ACROP and SIOPE recommendations for myeloablative total body irradiation in children.
7 Jun, 2022 | 10:52h | UTC
Oncologic emergencies and urgencies: A comprehensive review.
6 Jun, 2022 | 12:06h | UTCOncologic emergencies and urgencies: A comprehensive review – CA: A Cancer Journal for Clinicians
Commentary on Twitter
?Just in time for #ASCO22 | Oncologic emergencies and urgencies: A comprehensive review https://t.co/HyZmI37tr5 @BEGouldRothberg @YaleCancer @KeithDelman
CC: @OncoAlert pic.twitter.com/57tqiLXijN— CA: A Cancer Journal for Clinicians (@CAonline) June 2, 2022
#ASCO22 – RCT: Ibrutinib plus Bendamustine and Rituximab in untreated Mantle-Cell Lymphoma.
6 Jun, 2022 | 11:16h | UTCIbrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)
#ASCO22 – RCT: Triplet therapy, transplantation, and maintenance until progression in myeloma.
6 Jun, 2022 | 11:06h | UTCTriplet Therapy, Transplantation, and Maintenance until Progression in Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
DETERMINATION: Among adults with multiple myeloma, continuous lenalidomide maintenance therapy after triplet therapy (RVD, plus ASCT) associated with longer PFS than triplet therapy alone. #ASCO22 https://t.co/YhKgjc1Enz pic.twitter.com/cU8nefokZo
— NEJM (@NEJM) June 5, 2022
#ASCO22 – Phase 1-2 single-arm study: Teclistamab in relapsed or refractory multiple myeloma.
6 Jun, 2022 | 11:11h | UTCTeclistamab in Relapsed or Refractory Multiple Myeloma – New England Journal of Medicine
Commentary on Twitter
MajesTEC-1: Teclistamab resulted in a high incidence of deep and durable response in patients with triple-class–exposed relapsed or refractory multiple myeloma. #ASCO22 https://t.co/Nanjob1q7p pic.twitter.com/oqfaiu8MOx
— NEJM (@NEJM) June 5, 2022
Cohort Study: Risk of hematologic cancer in patients with undifferentiated pruritus.
30 May, 2022 | 10:35h | UTCRisk of Hematologic Cancer in Patients With Undifferentiated Pruritus – JAMA Dermatology (link to abstract – $ for full-text)
Commentary: Undifferentiated Pruritus Associated with Increased Risk of Hematologic Cancer – HCP Live
Cohort Study: Characteristics and natural history of early-stage cardiac transthyretin amyloidosis.
27 May, 2022 | 11:56h | UTCEditorial: Early-stage amyloid transthyretin cardiomyopathy: uncertainties and opportunities
Commentary on Twitter
The natural history of Transthyretin Amyloid Cardiomyopathy (ATTR-CM): disease course and clinical outcome among patients diagnosed with early-stage of disease!#amyloid #heart #failure #cardiac #amyloidosis@escardio @ESC_Journals
https://t.co/uvydC3gisD pic.twitter.com/ooKyjeGVNe
— EHJ Editor-in-Chief (@ehj_ed) May 25, 2022
Under a https://creativecommons.org/licenses/by-nc/4.0/ license
Navigating financial toxicity in patients with cancer: A multidisciplinary management approach.
26 May, 2022 | 10:57h | UTCRelated:
Not Just Nausea And Vomiting: Cancer Docs Now Worry About ‘Financial Toxicity’ – WBUR
Financial Toxicity and Cancer Treatment (PDQ®) – National Institute of Cancer
Second Revision of the International Staging System (R2-ISS) for overall survival in Multiple Myeloma.
26 May, 2022 | 10:34h | UTC
Cohort Study: Risk of venous thromboembolism in men with prostate cancer compared with men in the general population.
25 May, 2022 | 11:01h | UTCNews Release: Men with prostate cancer have a higher risk of serious blood clots – BMJ
Commentary on Twitter
Men with prostate cancer have a 50% higher risk of developing venous thrombosis during the 5 years following their cancer diagnosishttps://t.co/RrYAB5lSrb pic.twitter.com/VGMI7GILgE
— K Pavithran (@drkpavithran) May 24, 2022
Under a http://creativecommons.org/licenses/by-nc/4.0/ license
Identification of high-risk multiple myeloma with a plasma cell leukemia-like transcriptomic profile.
23 May, 2022 | 00:41h | UTC
Commentary on Twitter
A transcriptomic primary plasma cell leukaemia classifier comprising 53 genes had a sensitivity of 93% in pts with newly-diagnosed MM. Multivariate analysis confirmed the prognostic performance of this classifier vs the International Staging System: https://t.co/bD45PQG9bl #MMSM
— NatureRevClinOncol (@NatRevClinOncol) April 7, 2022
RCT: Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma.
19 May, 2022 | 10:39h | UTCAddition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial – The Lancet Haematology (link to abstract – $ for full-text)
Commentary: Elotuzumab Does Not Improve PFS in Newly Diagnosed Multiple Myeloma – Cancer Therapy Adviser
Commentary on Twitter
NEW research— Addition of elotuzumab to lenalidomide and dexamethasone did not improve progression-free survival in patients w/ newly diagnosed, transplantation ineligible multiple myeloma: results of the ph3 ELOQUENT-1 trial #mmsm https://t.co/8O3O6ikCJO pic.twitter.com/qe5V7Om9DN
— The Lancet Haematology (@TheLancetHaem) May 12, 2022